Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy [735]
Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, et al.
Record ID 32015000679
English
Details
Project Status:
Completed
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/145701/#/
Year Published:
2015
URL for published report:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/145701/#/
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Female
- Peritoneal Neoplasms
- BRCA2 Protein
- BRCA1 Protein
- Neoplasm Recurrence, Local
- Fallopian Tube Neoplasms
- Ovarian Neoplasms
- Phthalazines
- Piperazines
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.